Drug Approval | April 17, 2026
Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The goal is to better support drug developers as programs move from laboratory research into clinical trials
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
